Topical retinoids in acne - An evidence-based overview;Topische retinoide bei akne - Eine evidenzbasierte übersicht

JDDG - Journal of the German Society of Dermatology

Volumn 6, Issue 12, 2008, Pages 1023-1031

  Thielitz, Anja ^a   Abdel Naser, Mohamed B ^b,c   Fluhr, Joachim W ^d,e   Zouboulis, Christos C ^c   Gollnick, Harald ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c Klinik für Dermatologie Venerologie Allergologie und Immunologie   (Germany)

^d Bioskin   (Germany)

^e Bioskin Berlin   (Germany)

Author keywords

Acne; Evidence based medicine; Safety; Therapy; Topical retinoids

Indexed keywords

ADAPALENE; ANTIBIOTIC AGENT; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; ISOTREXIN; LYMECYCLINE; MICROSPHERE; MINOCYCLINE; PLACEBO; RETIN A MICRO; RETINAL; RETINOIC ACID; RETINOID; RETINOL; TAZAROTENE; TRETIN X; UNCLASSIFIED DRUG; ZIANA;

ACNE; ADD ON THERAPY; CLINICAL TRIAL; CREAM; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; DRY SKIN; ERYTHEMA; EVIDENCE BASED PRACTICE; GEL; HUMAN; MAINTENANCE THERAPY; METHODOLOGY; MONOTHERAPY; PREGNANCY; REVIEW; SAFETY; SKIN ABRASION; SKIN BURNING SENSATION; SKIN PRURITUS; UNITED STATES;

ACNE VULGARIS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; ERYTHEMA; EVIDENCE-BASED MEDICINE; HUMANS; RETINOIDS;

EID: 57649101399     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06741.x     Document Type: Review

References (91)

1. Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther 1992 14 : 773 780.
2. Thielitz A, Helmdach M, Ropke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001 145 : 19 27.
3. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007 21 : 747 753.
4. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003 49 : S1 37.
5. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003 49 : S200 S210.
6. Webster G. Mechanism-based treatment of acne vulgaris: the value of combination therapy. J Drugs Dermatol 2005 4 : 281 288.
7. Sackett D, Strauss S, Richardson W, Rosenberg W, Haynes R. Evidence-based medicine: how to practise and teach EBM. London: Churchill Livingstone, 2001 : 169 182.
8. Bikowski JB. Mechanisms of the come-dolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol 2005 4 : 41 47.
9. Kang S. The mechanism of action of topical retinoids. Cutis 2005 75 : 10 13.
10. Pechere M, Pechere JC, Siegenthaler G, Germanier L, Saurat JH. Antibacterial activity of retinaldehyde against Pro-pionibacterium acnes. Dermatology 1999 199 Suppl 1 : 29 31.
11. Jones DA. The potential immunomo-dulatory effects of topical retinoids. Dermatol Online J 2005 11 : 3.
12. Wolf JE, Jr. Potential anti-inflammatory effects of topical retinoids and reti-noid analogues. Adv Ther 2002 19 : 109 118.
13. Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner 1976 216 : 106 109.
14. Christiansen J, Holm P, Reymann F. The retinoic acid derivative Ro 11-1430 in Acne vulgaris. A controlled multi-center trial against retinoic acid. Der-matologica 1977 154 : 219 227.
15. Webster GF. Safety and efficacy of Tre-tin-X compared with Retin-A in patients with mild-to-severe acne vulgaris. Skinmed 2006 5 : 114 118.
16. Skov MJ, Quigley JW, Bucks DA. Topical delivery system for tretinoin: research and clinical implications. J Pharm Sci 1997 86 : 1138 1143.
17. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998 139 Suppl 52 : 34 40.
18. Quigley JW, Bucks DA. Reduced skin irritation with tretinoin containing po-lyolprepolymer-2, a new topical treti-noin delivery system: a summary of preclinical and clinical investigations. J Am Acad Dermatol 1998 38 : S5 10.
19. Berger R, Barba A, Fleischer A, Leyden JJ, Lucky A, Pariser D, Rafal E, Thiboutot D, Wilson D, Grossman R, Nighland M. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis 2007 80 : 152 157.
20. Berger R, Rizer R, Barba A, Wilson D, Stewart D, Grossman R, Nighland M, Weiss J. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vul-garis: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial. Clin Ther 2007 29 : 1086 1097.
21. Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol 1998 38 : S17 S23.
22. Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double-blind, vehicle-controlled, mul-ticenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol 1998 38 : S24 S30.
23. Mills OH, Jr., Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978 58 : 555 557.
24. Korting HC, Braun-Falco O. Efficacy and tolerability of combined topical treatment of acne vulgaris with treti-noin and erythromycin in general practice. Drugs Exp Clin Res 1989 15 : 447 451.
25. Kreusch J, Bextermoller R. Efficacy and tolerability of a topical erythromy-cin/tretinoin combination preparation in acne treatment: post-marketing surveillance study involving over 6500 patients. Curr Med Res Opin 2000 16 : 1 7.
26. Gupta AK, Lynde CW, Kunynetz RA, Amin S, Choi K, Goldstein E. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg 2003 7 : 31 37.
27. Handojo I. Retinoic acid cream (Airol cream) and benzoyl-peroxide in the treatment of acne vulgaris. Southeast Asian J Trop Med Public Health 1979 10 : 548 551.
28. Nyirady J, Lucas C, Yusuf M, Mignone P, Wisniewski S. The stability of treti-noin in tretinoin gel microsphere 0.1%. Cutis 2002 70 : 295 298.
29. Shalita AR, Rafal ES, Anderson DN, Yavel R, Landow S, Lee WL. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis 2003 72 : 167 172.
30. Zouboulis CC, Derumeaux L, Decroix J, Maciejewska-Udziela B, Cambazard F, Stuhlert A. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulga-ris. Br J Dermatol 2000 143 : 498 505.
31. Richter JR, Forstrom LR, Kiistala UO, Jung EG. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% treti-noin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol 1998 11 : 227 233.
32. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006 54 : 73 81.
33. Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfield L, Plott RT, Leyden J, Wortzman M ZIANA Study Group. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol 2007 6 : 607 615.
34. Bowman S, Gold M, Nasir A, Vamvakias G. Comparison of clin-damycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J Drugs Dermatol 2005 4 : 611 618.
35. Chalker DK, Lesher JL Jr., Smith JG Jr., Klauda HC, Pochi PE, Jacoby WS, Yonkosky DM, Voorhees JJ, Ellis CN, Matsuda-John S, et al. Efficacy of topical isotretinoin 0.05% gel in acne vul-garis: results of a multicenter, double-blind investigation. J Am Acad Dermatol 1987 17 : 251 254.
36. Dominguez J, Hojyo MT, Celayo JL, Dominguez-Soto L, Teixeira F. Topical isotretinoin vs. topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol 1998 37 : 54 55.
37. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002 147 : 523 527.
38. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical iso-tretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol 1992 17 : 165 168.
39. Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebo-controlled clinical trial to compare a gel containing a combination of isotreti-noin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology 1999 199 : 242 247.
40. Marazzi P, Boorman GC, Donald AE, Davies HD. Clinical evaluation of Double Strength Isotrexin versus Benz-amycin in the topical treatment of mild to moderate acne vulgaris. J Dermatolog Treat 2002 13 : 111 117.
41. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998 139 Suppl 52 : 48 56.
42. Ellis CN, Millikan LE, Smith EB, Chalker DM, Swinyer LJ, Katz IH, Berger RS, Mills OH Jr., Baker M, Verschoore M, Loesche C. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol 1998 139 Suppl 52 : 41 47.
43. Thiboutot D, Gold MH, Jarratt MT, Kang S, Kaplan DL, Millikan L, Wolfe J, Loesche C, Baker M. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001 68 : 10 19.
44. Pierard-Franchimont C, Henry F, Fraiture AL, Fumal I, Pierard GE. Split-face clinical and bio-instrumental comparison of 0.1% adapalene and 0.05% tretinoin in facial acne. Dermatology 1999 198 : 218 222.
45. Cunliffe WJ, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002 12 : 350 354.
46. Lucky A, Jorizzo JL, Rodriguez D, Jones TM, Stewart DM, Tschen EH, Kanof NB, Miller BH, Wilson DC, Loven KH. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris. Cutis 2001 68 : 34 40.
47. Thiboutot D, Pariser DM, Egan N, Flores J, Herndon JH Jr., Kanof NB, Kempers SE, Maddin S, Poulin YP, Wilson DC, Hwa J, Liu Y, Graeber M Adapalene Study Group. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol 2006 54 : 242 250.
48. Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis 2005 76 : 145 151.
49. Wolf JE Jr., Kaplan D, Kraus SJ, Loven KH, Rist T, Swinyer LJ, Baker MD, Liu YS, Czernielewski J. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003 49 : S211 S217.
50. Zhang JZ, Li LF, Tu YT, Zheng J. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004 15 : 372 378.
51. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, Kang S Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007 57 (5 791 799.
52. Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol 2007 6 : 616 622.
53. Cunliffe WJ, Meynadier J, Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Briantais P, Sidou F, Soto P. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003 49 : S218 S226.
54. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed 2005 4 : 138 146.
55. Shalita AR, Chalker DK, Griffith RF, Herbert AA, Hickman JG, Maloney JM, Miller BH, Tschen EH, Chandraratna RA, Gibson JR, Lew-Kaya DA, Lue JC, Sefton J. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999 63 : 349 354.
56. Shalita AR, Berson DS, Thiboutot DM, Leyden JJ, Parizadeh D, Sefton J, Walker PS, Gibson JR Tazarotene Cream in Acne Clinical Study Investigator Group. Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther 2004 26 : 1865 1873.
57. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001 67 : 4 9.
58. Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. Once-daily tazaro-tene 0.1% gel versus once-daily treti-noin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis 2002 69 : 12 19.
59. Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J. A multi-center, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis 2002 69 : 4 11.
60. Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a mul-ticenter, double-blind, randomized, parallel-group study. J Drugs Dermatol 2005 4 : 153 158.
61. Leyden J, Lowe N, Kakita L, Draelos Z. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001 67 : 10 16.
62. Bershad S, Kranjac Singer G, Parente JE, Tan MH, Sherer DW, Persaud AN, Lebwohl M. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002 138 : 481 489.
63. Draelos ZD, Tanghetti EA. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis 2002 69 : 20 29.
64. Tanghetti E, Abramovits W, Solomon B, Loven K, Shalita A. Tazarotene versus tazarotene plus clindamycin/ben-zoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. J Drugs Dermatol 2006 5 : 256 261.
65. Fort-Lacoste L, Verscheure Y, Tisne-Versailles J, Navarro R. Comedolytic effect of topical retinaldehyde in the rhino mouse model. Dermatology 1999 199 Suppl 1 : 33 35.
66. Poli F, Ribet V, Lauze C, Adhoute H, Morinet P. Efficacy and safety of 0.1% retinaldehyde/ 6% glycolic acid (diac-neal) for mild to moderate acne vulgaris. A multicentre, double-blind, randomized, vehicle-controlled trial. Dermatology 2005 210 Suppl 1 : 14 21.
67. Dréno B, Nocera T, Verrière F, Vienne MP, Ségard C, Vitse S, Carré C. Topical retinaldehyde with glycolic acid: study of tolerance and acceptability in association with anti-acne treatments in 1,709 patients. Dermatology 2005 210 Suppl 1 : 22 29.
68. Dreno B, Katsambas A, Pelfini C, Plantier D, Jancovici E, Ribet V, Nocera T, Morinet P, Khammari A. Combined 0.1% retinaldehyde/ 6% glycolic acid cream in prophylaxis and treatment of acne scarring. Dermatology 2007 214 : 260 267.
69. Morel P, Vienne MP, Beylot C, Bonérandi JJ, Dréno B, Lehucher-Ceyrac D, Slimani S, Dupuy P. Clinical efficacy and safety of a topical combination of retinaldehyde 0.1% with erythromycin 4% in acne vulgaris. Clin Exp Dermatol 1999 24 : 354 357.
70. Fluhr JW, Vienne MP, Lauze C, Dupuy P, Gehring W, Gloor M. Tolerance profile of retinol, retinaldehyde and reti-noic acid under maximized and long-term clinical conditions. Dermatology. 1999 199 Suppl 1 : 57 60.
71. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Kerrouche N, Arsonnaud S, Kang S. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006 142 : 597 602.
72. Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Kerrouche N, Sidou F, Soto P. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007 17 : 45 51.
73. Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, Shupack J. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol 2006 142 : 605 612.
74. Clucas A, Verschoore M, Sorba V, Poncet M, Baker M, Czernielewski J. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. J Am Acad Dermatol 1997 36 : S116 S118.
75. Brand B, Gilbert R, Baker MD, Poncet M, Greenspan A, Georgeian K, Soto P. Cumulative irritancy potential of adapa-lene cream 0.1% compared with adapa-lene gel 0.1% and several tretinoin formulations. Cutis 2003 72 : 455 458.
76. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapa-lene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%. Cutis 2005 75 : 238 243.
77. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapa-lene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%. Cutis 2005 75 : 289 293.
78. Brand B, Gilbert R, Baker MD, Poncet M, Greenspan A, Georgeian K, Soloff AM. Cumulative irritancy comparison of adapalene gel 0.1% versus other re-tinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003 49 : S227 S232.
79. Dosik JS, Gilbert RD, Arsonnaud S. Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies. Skinmed 2006 5 : 219 223.
80. Laquieze S, Czernielewski J, Rueda MJ. Beneficial effect of a moisturizing cream as adjunctive treatment to oral isotretinoin or topical tretinoin in the management of acne. J Drugs Derma-tol 2006 5 : 985 990.
81. Latriano L, Tzimas G, Wong F, Wills RJ. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of treti-noin and its metabolites after single doses or long-term use. J Am Acad Der-matol 1997 36 : S37 S46.
82. Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet 1993 341 : 1352 1353.
83. Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, Sarda P, Blayac JP. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother 1998 32 : 505 506.
84. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993 341 : 1181 1182.
85. Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. Minor malformations characteristic of the reti-noic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 2005 136 : 117 121.
86. Jensen BK, McGann LA, Kachevsky V, Franz TJ. The negligible systemic availability of retinoids with multiple and excessive topical application of isotreti-noin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol 1991 24 : 425 428.
87. Cunliffe WJ, Glass D, Goode K, Stables GI, Boorman GC. A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Derm Venereol 2001 81 : 14 17.
88. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997 36 : S96 103.
89. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapa-lene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol 1998 139 Suppl 52 : 8 11.
90. Autret E, Berjot M, Jonville-Bera AP, Aubry MC, Moraine C. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet 1997 350 : 339.
91. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000 43 : S31 S35.